PAX3	S-GENE
-	O
FOXO1	S-GENE
Establishes	O
Myogenic	O
Super	O
Enhancers	O
and	O
Confers	O
BET	O
Bromodomain	O
Vulnerability	O
.	O


Alveolar	O
rhabdomyosarcoma	O
is	O
a	O
life	O
-	O
threatening	O
myogenic	O
cancer	O
of	O
children	O
and	O
adolescent	O
young	O
adults	O
,	O
driven	O
primarily	O
by	O
the	O
chimeric	O
transcription	O
factor	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
.	O


The	O
mechanisms	O
by	O
which	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
dysregulates	O
chromatin	O
are	O
unknown	O
.	O


We	O
find	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
reprograms	O
the	O
cis	O
-	O
regulatory	O
landscape	O
by	O
inducing	O
de	O
novo	O
super	O
enhancers	O
.	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
uses	O
super	O
enhancers	O
to	O
set	O
up	O
autoregulatory	O
loops	O
in	O
collaboration	O
with	O
the	O
master	O
transcription	O
factors	O
MYOG	S-GENE
,	O
MYOD	S-GENE
,	O
and	O
MYCN	S-GENE
.	O


This	O
myogenic	O
super	O
enhancer	O
circuitry	O
is	O
consistent	O
across	O
cell	O
lines	O
and	O
primary	O
tumors	O
.	O


Cells	O
harboring	O
the	O
fusion	O
gene	O
are	O
selectively	O
sensitive	O
to	O
small	O
-	O
molecule	O
inhibition	O
of	O
protein	O
targets	O
induced	O
by	O
,	O
or	O
bound	O
to	O
,	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
-	O
occupied	O
super	O
enhancers	O
.	O


Furthermore	O
,	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
recruits	O
and	O
requires	O
the	O
BET	O
bromodomain	O
protein	O
BRD4	S-GENE
to	O
function	O
at	O
super	O
enhancers	O
,	O
resulting	O
in	O
a	O
complete	O
dependence	O
on	O
BRD4	S-GENE
and	O
a	O
significant	O
susceptibility	O
to	O
BRD	O
inhibition	O
.	O


These	O
results	O
yield	O
insights	O
into	O
the	O
epigenetic	O
functions	O
of	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
and	O
reveal	O
a	O
specific	O
vulnerability	O
that	O
can	O
be	O
exploited	O
for	O
precision	O
therapy	O
.	O
Significance	O
:	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
drives	O
pediatric	O
fusion	O
-	O
positive	O
rhabdomyosarcoma	O
,	O
and	O
its	O
chromatin	O
-	O
level	O
functions	O
are	O
critical	O
to	O
understanding	O
its	O
oncogenic	O
activity	O
.	O


We	O
find	O
that	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
establishes	O
a	O
myoblastic	O
super	O
enhancer	O
landscape	O
and	O
creates	O
a	O
profound	O
subtype	O
-	O
unique	O
dependence	O
on	O
BET	O
bromodomains	O
,	O
the	O
inhibition	O
of	O
which	O
ablates	O
PAX3	S-GENE
-	O
FOXO1	S-GENE
function	O
,	O
providing	O
a	O
mechanistic	O
rationale	O
for	O
exploring	O
BET	O
inhibitors	O
for	O
patients	O
bearing	O
PAX	O
-	O
fusion	O
rhabdomyosarcoma	O
.	O


Cancer	O
Discov	O
;	O
7	O
(	O
8	O
)	O
;	O
884	O
-	O
99	O
.	O


2017	O
AACR	O
.	O
This	O
article	O
is	O
highlighted	O
in	O
the	O
In	O
This	O
Issue	O
feature	O
,	O
p	O
.	O


783	O
.	O
